20.500.12556/RUL-136272 Polymorphism in gene for ABCC2 transporter predicts methotrexate drug survival in patients with psoriasis Background and Objectives: Methotrexate is widely prescribed for the treatment of moderateto-severe psoriasis. As drug survival encompasses efficacy, safety, and treatment satisfaction, such studies provide insights into successful drug treatments in the real-life scenario. The objective was to define methotrexate drug survival and reasons for discontinuation, along with factors associated with drug survival, in a cohort of adult patients with moderate-to-severe plaque psoriasis. Materials and Methods: Data on methotrexate treatment were extracted from our institutional registry. Drug survival was estimated by Kaplan–Meier analysis, and predictors of drug survival were analyzed by Cox proportional hazards regression. Results: We included 133 patients treated with methotrexate. Due to significant effects of the year of treatment initiation, drug survival analysis was performed for 117 patients who started methotrexate in 2010 or later. Median methotrexate drug survival was 11.0 months. Overall, 89% of patients discontinued treatment, with over half of these (51%) due to lack of efficacy. Significantly longer drug survival was seen for patients who discontinued treatment due to lack of efficacy versus drug safety (p = 0.049); when stratified by sex, this remained significant only for women (p = 0.002). The patient ABCC2 rs717620 genotype was significantly associated with drug survival in both univariate log-rank and multivariate Cox regression analyses, with variant T allele associated with longer drug survival (hazard ratio, 0.606; 95% confidence interval, 0.380–0.967; p = 0.036). Conclusions: We have identified the novel association of patient ABCC2 rs717620 genotype with methotrexate drug survival. This pharmacogenetic marker might thus help in the management of psoriasis patients in daily practice. psoriasis drug survival methotrexate pharmacogenetics metotreksat zdravljenje luskavice psoriaza farmakogenetika true false true Angleški jezik Slovenski jezik Članek v reviji 2022-04-21 14:59:43 2022-04-21 14:59:45 2022-09-15 04:13:40 0000-00-00 00:00:00 2021 0 0 12 str. iss. 10, art. 1050 Vol. 57 2021 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.517-085 1648-9144 10.3390/medicina57101050 79774723 medicina-57-01050-v2.pdf medicina-57-01050-v2.pdf 1 5A9A29310574538A3648B28EE2CDEF85 03ac667cd0962d5b0a09392daef1a80fec97a3a88228227f588644ae675a5f6f 3d261fc9-c173-11ec-8aca-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=155826 https://www.mdpi.com/1648-9144/57/10/1050 1 d999be4c-c172-11ec-8aca-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=155825 Fakulteta za farmacijo 0 0 0